For the purposes of the Disclosure Guidance and Transparency Rules, the Company is required to notify the market of the following:
During the month of April 2020, 906,905 Ordinary Shares were issued to support the allotment and issue of sales of 181,381 on aggregate of ADSs under the Company’s ATM Sales Agreement. Those Ordinary Shares were admitted to trading on AIM under the Company’s “US ADS ATM Placing Scheme” block listing.
As at the date of this announcement, the Company’s issued share capital consists of 160,766,883 ordinary shares with a nominal value of 3 pence each, with voting rights (“Ordinary Shares”). The Company does not hold any Ordinary Shares in Treasury.
Therefore the total number of Ordinary Shares in the Company with voting rights is 160,766,883 and this figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.
For further enquiries:
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 |
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner | +44 (0)20 7213 0883 |